Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001224962 XXXXXXXX LIVE 6 Common Stock, par value $0.001 per share 10/14/2025 false 0001454789 04635X102 Astria Therapeutics, Inc. 22 Boston Wharf Road 10th Floor Boston MA 02210 Alexander Rakitin (646) 205-5340 51 Astor Place, 10th Floor New York NY 10003 0001224962 N Perceptive Advisors LLC b AF N DE 0 6485420 0 6485420 6485420 N 11.5 IA 0001164426 N Joseph Edelman b AF N X1 0 6485420 0 6485420 6485420 N 11.5 IN 0001249675 N Perceptive Life Sciences Master Fund, Ltd. b WC N E9 0 4873721 0 4873721 4873721 N 8.6 CO 0001757940 N Perceptive Xontogeny Venture Fund, L.P. b WC N DE 0 1611699 0 1611699 1611699 N 2.9 CO Common Stock, par value $0.001 per share Astria Therapeutics, Inc. 22 Boston Wharf Road 10th Floor Boston MA 02210 Item 6 of the Schedule 13D is amended and supplemented as follows: On October 14, 2025, the Master Fund and Perceptive Xontogeny each entered into a Voting and Support Agreement (the "Voting Agreement") with BioCryst Pharmaceuticals, Inc. ("BioCryst"). Pursuant to the Voting Agreement, the Master Fund and Perceptive Xontogeny each agreed to vote their respective shares of Common Stock in favor of the adoption of the merger agreement between BioCryst, the Issuer, and Axel Merger Sub, Inc. dated October 14, 2025 (the "Merger Agreement") with respect to the proposed acquisition of the Issuer by BioCryst (the "Merger") and the approval of the transactions contemplated thereby, and, subject to certain exceptions, not to transfer their shares of Common Stock prior to the earlier of the effective time of the Merger and the termination of the Merger Agreement. The Master Fund and Perceptive Xontogeny each also consented to the treatment of their respective shares of Series X Convertible Preferred Stock and Warrants as set forth in the Merger Agreement. The Voting Agreements will terminate upon the earlier of the effective time of the Merger, their termination by written notice from BioCryst, any amendment of any term or provision of the Merger Agreement that reduces the consideration to be received by holders of Common Stock, and the termination of the Merger Agreement. The foregoing description of the Voting Agreements is qualified in its entirety by reference to the terms of the agreements, the form of which is filed as Exhibit 8 to this Schedule 13D and incorporated by reference into this Item 6. Item 7 of the Schedule 13D is amendmed and supplemented as follows: Exhibit 8 Form of Voting and Support Agreement (incorporated by reference to Exhibit 99.1 to Astria Therapeutics, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 14, 2025) Perceptive Advisors LLC /s/ Joseph Edelman Joseph Edelman, Managing Member 10/16/2025 Joseph Edelman /s/ Joseph Edelman Joseph Edelman 10/16/2025 Perceptive Life Sciences Master Fund, Ltd. /s/ Joseph Edelman By: Perceptive Advisors LLC, By: Joseph Edelman, Managing Member 10/16/2025 Perceptive Xontogeny Venture Fund, L.P. /s/ Joseph Edelman By: Perceptive Xontogeny Ventures GP, LLC; By: Joseph Edelman, Managing Member 10/16/2025